Dana-Farber Research News 05.15.2026 - Takeaways - MDSpire

Dana-Farber Research News 05.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 16 - 30.

  • May 15, 2026

  • 21 min

Share

  • 1

    Dana-Farber's Research News highlights recent studies by faculty, focusing on advancements in cancer research published from April 16 to 30, 2026.

  • 2

    Chronic lymphocytic leukemia (CLL) research emphasizes the need for curative therapies, especially for high-risk patients with specific genetic disruptions.

  • 3

    A study identified cycling regulatory T cells as key players in immune escape during breast cancer progression, suggesting new immuno-oncology targets.

  • 4

    Transposable elements are proposed as a new hallmark of cancer, contributing to inflammation and anti-tumor immune responses during oncogenic transformation.

  • 5

    The LEAP-010 study evaluates the efficacy of pembrolizumab combined with lenvatinib as first-line therapy for recurrent or metastatic head and neck cancer.

Original Source(s)

Dana-Farber Research News 05.15.2026

  • May 15, 2026

Related Content

This Week's CGT News: First Treg Therapy Approved

First Treg-based cell therapy approved, FDA advanced therapy office faces fresh turnover, and preclinical CAR T studies target rare blood cancers and glioblastoma

  • July 7, 2026

  • 6 min
Surgical Manual from Roswell Park Created to Advance Bladder Cancer Surgery Worldwide

Roswell Park Comprehensive Cancer Center announces the release of a new operative surgical manual authored by Khurshid Guru, MD.

  • by

  • July 8, 2026

  • 5 min
The Power List 2026 is Live

We celebrate 60 inspiring individuals helping turn pharma’s boldest ideas into reality

  • July 21, 2026

  • 1 min